Hepatitis B Does Not Increase Risk For Pancreatic Cancer
Posted on: Sunday, 1 November 2009, 06:00 CST
A Henry Ford Hospital study found that hepatitis B does not increase the risk for pancreatic cancer – and that only age is a contributing factor.
The results contradict a previous study in 2008 that suggested a link between pancreatic cancer and previous hepatitis B infection. Hepatitis B is an inflammation of the liver caused by a viral infection.
Study results will be presented at the American Association for the Study of Liver Diseases' Annual Meeting in Boston.
Using data from Henry Ford Health System, physicians looked at more than 74,000 patients who were tested for hepatitis B between 1995 and 2008. In the overall analysis, only age was found to be a significant predictor for pancreatic cancer.
"We looked at the incidence of pancreatic cancer among hepatitis B-infected patients over a 13-year period and found that we could not confirm a higher risk for those with a previous exposure to hepatitis B, as a prior study suggested," says Jeffrey Tang, M.D., gastroenterologist at Henry Ford Hospital and lead author of the study.
"When other factors are considered – such as age, race, sex, HIV status, and the presence of diabetes – only older age and presence of diabetes proved significant, whereas prior exposure to hepatitis B was no longer an important variable."
According to the National Cancer Institute, more than 35,000 people in the U.S. die of pancreatic cancer each year and 42,000 new cases are diagnosed. The survival rates for patients with pancreatic cancer are poor.
An estimated 800,000 to 1.4 million people have chronic hepatitis B infection, according to the Centers for Disease Control and Prevention. In 2007, an estimated 43,000 people in the United States were newly infected with hepatitis B, although many cases are not reported because many people do not have symptoms.
---
On the Net:
Related Articles
- Review Finds Conflicts Of Interest In Many Cancer Studies
- Jennerex Completes Treatment for First Patient Cohort in Phase I Cancer Study
- Epigenomics Reports Positive Results From Prostate Cancer Study
- CuraGen Initiates Phase II Breast Cancer Study
- Minister Clement Helps Launch Landmark Cancer Study
- ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
- Progen Presents Additional Analysis of Data From PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
- EpiCept Initiates Advanced Cancer Study
- Tenet Receives Grant From Robert Wood Johnson Foundation; 18-Month Project to Study Impact of Rapid Response Teams on Patient Safety
- IRX Therapeutics Enrolls First Patients in IRX-2 Phase II Head and Neck Cancer Study
 |
 |
User Comments (0)
RSS Feeds